Tarn Taran's Second Phase of War Against Drugs Begins
Tarn Taran police intensify the war on drugs with Phase 2. SSP Ranjit Singh leads a major crackdown, seizing assets and arresting peddlers. Read the full strategy.
Category : Search result: generic drugs opportunity
Trump on weight-loss drugs: 'No, I have not. I probably should.'
In a NYT interview, Donald Trump revealed he hasn't used GLP-1 drugs like Ozempic, sparking debate on obesity, healthcare costs, and his administration's drug price policies. Read the full story.
Trump Approves Sanctions Bill Against Russia
Former US President Donald Trump has endorsed a sanctions bill targeting Russia for its war in Ukraine. The move signals a potential shift in his stance. Read the full details and implications.
Natco Pharma Sues to Revoke Novo Nordisk's Semaglutide Patent
Natco Pharma files suit in Delhi High Court seeking revocation of Novo Nordisk's patent on diabetes drug semaglutide. Court issues notice, hearing set for Feb 5. Indian pharma race for generic Ozempic heats up.
Why Indian Drug Makers Challenge Global Patents
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
Generic Drugs as Good as Brands, Cost Far Less: Study
A citizen-funded study finds generic medicines, including Jan Aushadhi, match quality of expensive brands. Experts urge trust in affordable options for better treatment adherence. #Healthcare #India
Machado's $1.7 Trillion Venezuela Privatisation Plan
Nobel laureate María Corina Machado outlined a radical $1.7 trillion economic transformation for Venezuela via privatisation in 2025, aiming to reverse socialist policies. Read the full blueprint.
Novo Nordisk: Wegovy Price Cut to Boost India Obesity Therapy 5-7x
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Generic Semaglutide to Create Rs 50,000 Cr Market
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Generic Semaglutide to Create Rs 50bn+ Revenue Opportunity
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Semaglutide Patent Expiry Creates Rs 50,000 Cr Opportunity
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
Weight-loss drugs poised for takeoff, cancer care expands in 2026
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
Indian Pharma Firms Eye Licensing Deals for Obesity Drugs
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
India's 2025 Health Shift: Prevention, Generics & Digital Tools
From preventive screenings to affordable generics, 2025 reshaped India's health priorities. Discover the key trends that made wellness a daily habit and what it means for 2026.
Silver Investment: 342% Return Masks a Poor Decision
An investor made 342% profit on silver bought in 2013 but calls it a poor investment. Discover why the 13-year journey reveals critical lessons on thesis, timing, and opportunity cost compared to gold and equities.
Gaurav Mittal's 2026 Prediction: Gold, Silver, MSME Stocks
Market expert Gaurav Mittal predicts massive 2026 opportunities in gold, silver, and MSME stocks. Discover his unique insights combining market trends and planetary movements for wealth creation.
Bengaluru engineer arrested for making drugs at home
A Bengaluru software engineer was arrested for allegedly manufacturing synthetic drugs like MDMA in a makeshift home laboratory. Police seized drugs worth lakhs and equipment. Read the shocking details.
DCA Raids Quack's Clinic, Seizes Illegal Drugs Worth ₹15,011
Drugs Control Administration officials raided an unlicensed clinic in Karimnagar, seizing illegal steroids and antibiotics. The crackdown highlights the public health risks of unauthorized drug sales. Read more.
India's Weight-Loss Drug Market to Grow 10x by 2030
Explore the social and economic impact of GLP-1 drugs like Ozempic & Mounjaro in India. A ₹1,000 crore market is poised for massive growth. Share your thoughts.
Zota Health Raises ₹350 Crore, Signs Dhoni & Shetty
Zota Health Care secures ₹350 crore from investors via QIP to fund expansion. MS Dhoni & Suniel Shetty join as brand ambassadors. Aim to open 5000+ generic pharmacy stores by 2029.
Orange Biotech PCD Pharma Franchise: Lucrative Business Opportunity
Orange Biotech Private Limited unveils a nationwide PCD pharma franchise with high-profit margins, monopoly rights, and extensive product portfolio for entrepreneurs. Start your own pharma business today!
Ajanta Pharma & Biocon Partner for Generic Weight Loss Drug
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
GLP-1 Drugs Show Benefits Beyond Weight Loss
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
India Pharma Targets $500B, Innovation Hub by 2047
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Lack of Drug Inspectors Hampers Action on Spurious Drugs
A severe shortage of drug inspectors is hampering enforcement against spurious and adulterated medicines in India. Officials admit the staffing crisis is a major hurdle. Read more on the critical public health issue.
India's Big AI Opportunity: Stanford Professor Explains
Stanford Professor Susan Athey highlights India's unique chance to lead in customised AI solutions. Global models lack local context, creating a massive domestic market for implementation-focused innovation.
Govt's Data Exclusivity Push May Hit Cheap Generic Drugs
The Indian government is considering data exclusivity for pharma, a move that could delay cheap generic drugs, impact India's global edge, and affect medicine access. Read the full analysis.
Himachal Leads Nation in Substandard Drugs: 49 Fail
Himachal Pradesh reports the highest number of substandard drug samples in India. 49 samples failed quality tests, raising serious concerns about public health and pharmaceutical regulation.
Jan Aushadhi Kendra rules changed: 500-meter gap enforced
The Indian government mandates a 500-meter distance between Jan Aushadhi Kendras in major cities to protect store viability and ensure access to affordable generic medicines. Learn about the new policy's impact.
Supreme Court to Hear Bikram Majithia's Bail Plea on July 15
The Supreme Court has agreed to hear SAD leader Bikram Singh Majithia's plea for bail in a drugs case. The hearing is scheduled for July 15. Read the latest legal developments.
Page 1 of 4